Vol. 22 No. 1 (2016)

Published: 2016-05-05

Commentary

An Impediment to Personalized Medicine Commercialization is the Lack of Understanding of the Value of the Testing

Anthony Johnson
- Requires Subscription PDF (USD 25)

Article

Biopharmaceutical Startupâ€™s Need of a Regulatory Strategy

Julia Schueler, Tobias Ostler
- Requires Subscription PDF (USD 25)
Marketing authorization of medical devices in China

Weifan Zhang, Rebecca Liu, Chris Chatwin
- Requires Subscription PDF (USD 25)
VC-backed Biotechnology Firms: What is Entrepreneursâ€™ Return?

Demetris Iacovides
- Requires Subscription PDF (USD 25)
Encouraging Innovation in Preventive Health Technology: A Spotlight on Women's Health

Elizabeth Ann McCaman
- Requires Subscription PDF (USD 25)
Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver

Kristina M Lybecker
- Requires Subscription PDF (USD 25)
Using a Rasch Model to Rank Big Pharmaceutical Firms by Financial Performance

Thani Jambulingam, Carolin Schellhorn, Rajneesh Sharma
- Requires Subscription PDF (USD 25)

Conference Report

Moving from preclinical research to development

Vasu Pestonjamasp
- Requires Subscription PDF (USD 25)